Table 2 Adverse events during induction treatment, n (%).
Total N = 176 | ATO N = 85 | RIF N = 91 | p | |
|---|---|---|---|---|
Differentiation syndrome | ||||
Moderate | 11 (6.3) | 7 (8.2) | 4 (4.4) | 0.293 |
Severe | 1 (0.6) | 1 (1.2) | 0 (0) | 0.483 |
Infection/FUO | 134 (76.1) | 65 (76.5) | 69 (75.8) | 0.920 |
PCT | 28 (15.9) | 13 (15.3) | 15 (16.5) | 0.829 |
Coagulopathy events | ||||
Hemorrhage | 8 (4.5) | 3 (3.5) | 5 (5.5) | 0.721 |
Thrombosis | 3 (1.7) | 3 (3.5) | 0 (0) | 0.111 |
Liver | ||||
Grade 1–2 | 19 (10.8) | 11 (12.9) | 8 (8.8) | 0.375 |
Grade 3–4 | 0 (0) | 0 (0) | 0 (0) | - |
Cardiac | ||||
Grade 1–2 | 1 (0.6) | 1 (1.2) | 0 (0) | 0.483 |
Grade 3–4 | 1 (0.6) | 1 (1.2) | 0 (0) | 0.483 |
Gastrointestinal reaction | ||||
Grade 1–2 | 49 (27.8) | 25 (29.4) | 24 (26.4) | 0.653 |
Grade 3–4 | 0 (0) | 0 (0) | 0 (0) | - |
Rash | 11(6.3) | 5 (5.9) | 6 (6.6) | 0.845 |
Hyperlipemia | 1(0.6) | 0 (0) | 1 (1.1) | 1.000 |
